<?xml version="1.0" encoding="UTF-8"?>
<p id="para30">Remdesivir was first developed in the mid-2010s to fight Ebola. Although it was found to be ineffective against that virus, it showed promise in early trials against coronaviruses such as the one that causes SARS. That's why many hope it will work against the new coronavirus, SARS-CoV-2. The demand is already so high that its manufacturer, 
 <ext-link ext-link-type="uri" xlink:href="https://www.gilead.com/purpose/advancing-global-health/covid-19" id="interrefs30" xmlns:xlink="http://www.w3.org/1999/xlink">Gilead Sciences</ext-link>, recently had to 
 <ext-link ext-link-type="uri" xlink:href="https://www.nytimes.com/2020/03/23/health/coronavirus-drugs-remdesivir.html" id="interrefs40" xmlns:xlink="http://www.w3.org/1999/xlink">stop providing access</ext-link> for people outside of trials seeking the drug under compassionate-use schemes for untested medicines.
</p>
